Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking the drugmaker's Foundayo, as the company tries to catch up to a lead in the space established by rival Novo. Ricks spoke with CNBC in front of the roughly 240 acres of land that will eventually host Lilly's new $6.5 billion manufacturing facility at Generation Park in Houston, Texas. The company on Monday broke ground on the upcoming site nearly a year after first announcing it, and said it expects the plant to be operational by 2030. The facility will most notably produce Lilly's closely watched GLP-1 pill for obesity, Foundayo, which entered the U.S. market in April.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.